Patents by Inventor Michael James Orwat

Michael James Orwat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors
    Patent number: 6750225
    Abstract: The present application describes 1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-ones of the following formula or pharmaceutically acceptable salt forms thereof: wherein ring Rb is 3-amido or 4-methoxy, Ra can be cyano, trifluoromethyl, or amido, and R can be a substituted phenyl, a substituted imidazolyl, or a substituted pyridine. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
    Type: Grant
    Filed: April 17, 2002
    Date of Patent: June 15, 2004
    Assignee: Bristol-Myers Squibb Pharms Company
    Inventors: Donald Joseph Philip Pinto, Robert Anthony Galemmo, Jr., Michael James Orwat, Mimi Lifen Quan
  • Nitrogen containing heteroaromatics as factor Xa inhibitors
    Patent number: 6548512
    Abstract: The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein J is N or NH and D may be C(═NH)NH2, which are useful as inhibitors of factor Xa.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: April 15, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Donald Joseph Phillip Pinto, James Russell Pruitt, Joseph Cacciola, John Matthew Fevig, Qi Han, Michael James Orwat, Mimi Lifen Quan, Karen Anita Rossi
  • 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors
    Publication number: 20020177713
    Abstract: The present application describes 1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-ones of the following formula or pharmaceutically acceptable salt forms thereof: 1
    Type: Application
    Filed: April 17, 2002
    Publication date: November 28, 2002
    Inventors: Donald Joseph Philip Pinto, Robert Anthony Galemmo, Michael James Orwat, Mimi Lifen Quan
  • Carbocyclic heterocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
    Patent number: 6110910
    Abstract: This invention relates to carbocyclic and heterocyclic fused-ring quinolinecarboxylic acid compounds, to pharmaceutical compositions comprising such compounds, and to methods of using such compounds for the treatment and/or prevention of organ transplantation rejection, graft versus host disease, autoimmune diseases, chronic inflammatory diseases, including but not limited to psoriasis and rheumatoid arthritis, and cancer in a mammal.
    Type: Grant
    Filed: November 18, 1998
    Date of Patent: August 29, 2000
    Assignee: Dupont Pharmaceuticals
    Inventors: Ronald Louis Magolda, William John Pitts, Irina Cipora Jacobson, Carl Henry Behrens, Michael James Orwat, Douglas Guy Batt
  • Nitrogen containing heteroaromatics as factor Xa inhibitors
    Patent number: 6020357
    Abstract: The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula I: ##STR1## or pharmaceutically acceptable salt or prodrug forms thereof, wherein J is N or NH and D may be C(.dbd.NH)NH.sub.2, which are useful as inhibitors of factor Xa.
    Type: Grant
    Filed: December 22, 1997
    Date of Patent: February 1, 2000
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Donald Joseph Phillip Pinto, James Russell Pruitt, Joseph Cacciola, John Matthew Fevig, Qi Han, Michael James Orwat, Mimi Lifen Quan, Karen Anita Rossi
  • Prostaglandin synthase inhibitors
    Patent number: 5932586
    Abstract: This invention relates to ortho substituted phenyl compounds as inhibitors of prostaglandin synthase, to pharmaceutical compositions comprising such compounds and to methods of using such compounds as antiinflammatory and antipyretic agents.
    Type: Grant
    Filed: November 19, 1996
    Date of Patent: August 3, 1999
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Douglas Guy Batt, Donald Joseph Phillip Pinto, Michael James Orwat, Joseph James Petraitis, William John Pitts
  • Carbocyclic and hetertocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
    Patent number: 5874441
    Abstract: This invention relates to carbocyclic and heterocyclic fused-ring quinolinecarboxylic acid compounds, to pharmaceutical compositions comprising such compounds, and to methods of using such compounds for the treatment and/or prevention of organ transplantation rejection, graft versus host disease, autoimmune diseases, chronic inflammatory diseases, including but not limited to psoriasis and rheumatoid arthritis, and cancer in a mammal.
    Type: Grant
    Filed: March 18, 1997
    Date of Patent: February 23, 1999
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Ronald Louis Magolda, William John Pitts, Irina Cipora Jacobson, Carl Henry Behrens, Michael James Orwat, Douglas Guy Batt
  • (2-quinoxalinyloxy) phenoxypropanoic acids and related derivatives as anticancer agents
    Patent number: 5696119
    Abstract: This invention relates to (2-quinoxalinyloxy)phenoxypropanoic acids, related derivatives thereof, enantiomeric and diastereomeric forms thereof, mixtures of enantiomeric diastereomeric forms thereof, and pharmaceutically acceptable salt forms thereof, pharmaceutical compositions containing them, processes for their preparation, and methods of using them to treat cancer, particularly solid tumors, in mammals.
    Type: Grant
    Filed: December 28, 1994
    Date of Patent: December 9, 1997
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Carl Henry Behrens, Betsy Ann Dusak, Barbara Ann Harrison, Michael James Orwat
  • Carbocyclic and heterocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
    Patent number: 5639759
    Abstract: This invention relates to carbocyclic and heterocyclic fused-ring quinolinecarboxylic acid compounds, to pharmaceutical compositions comprising such compounds, and to methods of using such compounds for the treatment and/or prevention of organ transplantation rejection, graft versus host disease, autoimmune diseases, chronic inflammatory diseases, including but not limited to psoriasis and rheumatoid arthritis, and cancer in a mammal.
    Type: Grant
    Filed: March 27, 1995
    Date of Patent: June 17, 1997
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Ronald Louis Magolda, William John Pitts, Irina Cipora Jacobson, Carl Henry Behrens, Michael James Orwat, Douglas Guy Batt